A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia
The study will determine the maximal tolerated dose (MTD) of panobinostat administered in combination with a fixed combination of cytarabine (ara-C) and mitoxantrone in adult patients with relapsed or refractory acute myeloid leukemia (AML).
Acute Myeloid Leukemia
DRUG: panobinostat/LBH589B
Incidence of dose limiting toxicity (DLT), 1 cycle (1 cycle = 28 days)
Frequency, severity and duration of Adverse Events (AE) using CTCAE version 3.0, During maximal three LBH589/chemotherapy cycles and subsequent optional single-agent LBH589 treatment
The study will determine the maximal tolerated dose (MTD) of panobinostat administered in combination with a fixed combination of cytarabine (ara-C) and mitoxantrone in adult patients with relapsed or refractory acute myeloid leukemia (AML).